Financial Performance - The group recorded revenue of approximately HKD 1,833,795,000 for the year, a slight increase from HKD 1,833,038,000 in the previous year, representing a growth of 0.04%[3] - The net loss for the group was approximately HKD 158,207,000, compared to a net loss of HKD 159,089,000 in the previous year, indicating a reduction in loss of 0.55%[3] - The total comprehensive loss attributable to the company's owners was HKD 257,087,000, compared to HKD 231,360,000 in the previous year, representing an increase in loss of 11.09%[5] - The basic and diluted loss per share increased to HKD 3.01 from HKD 2.87, indicating a worsening of loss per share by 4.87%[5] - The company reported a pre-tax loss of HKD 120,863 for the year, reflecting challenges in various segments[25] - The company reported a net loss attributable to shareholders of 203,703,000 HKD for 2024, compared to a loss of 194,210,000 HKD in 2023, indicating an increase in losses of 4.8%[34] Assets and Liabilities - The group's total assets decreased to approximately HKD 3,380,347,000 from HKD 3,618,746,000, reflecting a decline of 6.58%[3] - The group's non-current assets decreased to HKD 2,232,058,000 from HKD 2,558,678,000, a decline of 12.76%[6] - The total liabilities decreased slightly to HKD 594,198,000 from HKD 597,372,000, a reduction of 0.46%[7] - The group's bank borrowings decreased to HKD 80,683,000 from HKD 87,563,000, with non-current liabilities amounting to HKD 63,089,000[42] - The group's expected credit loss provision for other receivables was approximately HKD 6,704,000, compared to zero in the previous year[43] - The company's receivables and other receivables totaled 462,852,000 HKD in 2024, down from 511,071,000 HKD in 2023, reflecting a decrease of 9.4%[38] Revenue Breakdown - Revenue from Hong Kong medical services reached HKD 787,053,000, an increase from HKD 770,996,000 in the previous year, representing a growth of 2.9%[16] - Revenue from mainland China hospital management and medical services was HKD 546,615,000, down from HKD 552,795,000, reflecting a decrease of 1.1%[16] - The company reported a total service income of HKD 1,819,007,000 under the gross basis, compared to HKD 1,817,027,000 in the previous year, showing a marginal increase of 0.1%[18] - Revenue from Hong Kong was HKD 1,287,180, up from HKD 1,280,243 in the previous year, while revenue from other regions in China decreased to HKD 546,615 from HKD 552,795[26] Dividends and Shareholder Returns - The group proposed a final dividend of HKD 0.12 per share, unchanged from the previous year[2] - The company declared a final dividend of 0.12 HKD per share for 2024, consistent with the dividend declared for 2023, totaling approximately 8,128,000 HKD[33] Operational Developments - The company has established a comprehensive service system covering primary to high-end cross-specialty medical services, enhancing its competitive advantage and market share[61] - The company has expanded its health management operations in mainland China, responding to the rising demand for healthcare due to an aging population and increasing chronic disease rates[55] - The company has implemented cost control measures and improved operational efficiency to enhance overall competitiveness amid economic uncertainties and industry challenges[54] - The group is actively seeking potential acquisition opportunities in Hong Kong and mainland China to expand its operational scale[85] Employee and Cost Management - The total employee cost for the year was approximately HKD 743,697,000, compared to HKD 740,650,000 in 2023, with 1,441 employees hired, an increase from 1,399 in the previous year[91] - The company reported a total employee cost of 743,697,000 HKD for 2024, a marginal increase from 740,650,000 HKD in 2023[32] Future Outlook and Strategic Initiatives - The company plans to leverage its medical resources to support the Hong Kong government's primary healthcare initiatives, enhancing collaboration on community health programs[78] - The group plans to open three general medical centers and one pediatric center in Sha Tin by Q1 2025, enhancing primary and multi-specialty services[80] - The group aims to strengthen its specialist brand presence in densely populated communities, with a new cardiology center opening in Tuen Mun by Q1 2025[80] - The group will establish a medical advisory committee to ensure compliance with legal and social needs while enhancing the quality of medical services[80] Market Position and Customer Engagement - Major customer A accounted for 21% of total revenue in 2024, down from 22% in 2023, indicating a slight diversification in customer base[28] - The company has developed a strong customer base in health management, demonstrating the effectiveness of its forward-looking operational strategies in mainland China[55] - TBMG has built a complete customer database, utilizing big data to enhance customer satisfaction and retention through personalized services[76] Compliance and Governance - The group has received approval from its auditor for the consolidated financial statements for the year, confirming the accuracy of the reported figures[107] - The executive directors include the chairman and CEO, along with several other key members, indicating a stable leadership structure[110]
康健国际医疗(03886) - 2024 - 年度业绩